Switzerland: medical cannabis snapshot
25th August 2023 | Market reports , Regulatory reports |
This snapshot offers an overview of Switzerland’s medical cannabis market and its regulations
This snapshot offers an overview of Switzerland’s medical cannabis market and its regulations
CannIntelligence has analysed regulations and contacted authorities in the majority of European countries to determine the legality of IHDCs. This report presents our findings
This snapshot of Switzerland’s CBD and cannabis sector covers both the regulatory framework for CBD as well as cannabis (recreational and medical) and offers an overview of the market, online retailers and consumer preferences
This report offers a detailed overview of Switzerland’s regulatory regime for cannabis, CBD and hemp, covering all policy areas and discussing future changes to the law
CBD-Intel has compiled and classified regulatory data on medical and recreational cannabis in over 50 jurisdictions around the world. This report is accompanied by a detailed database outlining the regulatory situation in selected countries
Hemp flowers are treated similarly in Europe to all other hemp-derived CBD products in that market restrictions differ from country to country
Switzerland is currently experiencing important changes in its cannabis regulation. This report details the current regulatory framework for hemp, CBD and cannabis, and provides information on forthcoming changes
The CBD industry navigates a complex and changing regulatory landscape across the world, with parts of the industry operating in a grey area. This is particularly the case for one of the most popular product categories on the market: edibles
The regulatory landscape for CBD products varies across the world and constantly changing, making compliance a potential minefield. This report provides an overview of the current legal status of CBD cosmetics in key markets around the world
CBD is not a scheduled substance in Switzerland, and its legality in the finished product depends on the intended use. This inevitably leads to a somewhat confusing regulatory framework with many different rules and restrictions
In this overview of Swiss CBD regulation, we find that THC content is limited to 0.3% in cannabis plants and 1% in finished products, significantly higher than most neighbouring countries
CBD products in Switzerland come under three possible headings: sale with some restrictions; sale requiring authorisation; and sale prohibited. This report considers these three categories, what they apply to, and what they mean
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.